+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Medications for Erectile Dysfunction Market - Global Forecast 2025-2030- Product Image
Oral Medications for Erectile Dysfunction Market - Global Forecast 2025-2030- Product Image
Sale

Oral Medications for Erectile Dysfunction Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131456
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oral erectile dysfunction medication market continues to evolve rapidly, fueled by scientific innovation, digital integration, and shifts in patient expectations. With reliable efficacy and broadening accessibility, senior stakeholders face a dynamic competitive landscape shaped by technology, demographic transitions, and regulatory adjustments.

Market Snapshot: Oral Erectile Dysfunction Therapies

The oral erectile dysfunction therapies market demonstrates robust growth supported by increasing patient awareness, expanding geographic reach, and ongoing compound development. The landscape is defined by the emergence of both branded and generic solutions and is characterized by intensified competition, evolving consumer demographics, and significant technological adoption in distribution and prescription models. The sector is further bolstered by rising investments in healthcare digitalization, allowing for streamlined access to treatment and enhanced patient engagement through telemedicine, especially in underserved regions.

Scope & Segmentation

Defining a comprehensive view, this report addresses major categories and influential dynamics within the oral erectile dysfunction medication sector.

  • Active Compound Types: Avanafil, Sildenafil, Tadalafil, Vardenafil
  • Dosage Strengths: 5 mg, 10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 200 mg
  • Brand Classification: Branded (including Cialis, Levitra, Stendra, Viagra) and Generic (such as Avanafil, Sildenafil Citrate, Tadalafil, Vardenafil)
  • Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
  • Age Segments: Under 45 Years, 45-60 Years, 60+ Years
  • Regional Markets: Americas, Europe, Middle East & Africa, Asia-Pacific, with coverage across key sub-regions including the United States, Canada, Brazil, United Kingdom, China, India, Japan, and others
  • Key Companies: Pfizer Inc., Eli Lilly and Company, Bayer AG, Vivus, Teva, Viatris Inc., Sandoz, Dr. Reddy's, Cipla, Sun Pharma
  • Technologies & Innovations: Digital health integration, telemedicine consultation, data analytics for dosing personalization, online prescription platforms, process chemistry advances

Key Takeaways: Strategic Insights and Market Forces

  • Oral treatments have become the predominant first-line option for erectile dysfunction, with a strong shift toward patient convenience, adherence, and customizable regimens.
  • Digital health and telemedicine platforms are enabling tailored experiences, from remote consultation to prescription management, directly enhancing therapy adherence across diverse populations.
  • The transition to generic medications, enabled by patent expirations, intensifies competition while widening access, requiring established brands to innovate through formulation and delivery advancements.
  • Segmented marketing and targeted product development strategies are crucial, as preferences and adoption patterns differ by age, region, and healthcare infrastructure.
  • Technological collaborations and supply chain diversification support resilience against disruptions, facilitate faster market entry, and optimize manufacturing agility.
  • Regulatory shifts, including approval process reforms, continue to impact product lifecycle and competitive entry worldwide.

Tariff Impact: U.S. Policy Shifts and Supply Chain Strategies

Anticipated U.S. tariff changes in 2025 impact both active pharmaceutical ingredients and finished oral erectile dysfunction products. Manufacturers face higher import duties on key intermediates, prompting a critical review of sourcing strategies and supply chain resilience. Companies are diversifying suppliers, investing in domestic production, and renegotiating contracts to protect cost structure and mitigate risks from global trade uncertainties. Process innovations and strategic stockpiling are being adopted to stabilize drug availability and pricing in the evolving regulatory climate.

Methodology & Data Sources

This report is built on primary interviews with key opinion leaders (urologists, procurement specialists, supply-chain executives) and an exhaustive review of peer-reviewed journals, regulatory filings, and clinical trial records. Data were validated using triangulation methods, ensuring the accuracy and robustness of insights through stringent quality control and continuous feedback engagement.

Why This Report Matters

  • Enables decision-makers to identify emerging opportunities and optimize product positioning in a competitive and regulated marketplace.
  • Highlights actionable pathways for digital transformation, demographic targeting, and operational agility to drive sustainable commercial growth.
  • Informs strategic responses to global supply disruptions and competitive pressures, supporting policy adaptation and informed investment planning.

Conclusion

The oral erectile dysfunction therapies sector continues to transform through innovation, technology adoption, and diversified market strategies. Stakeholders equipped with the insights from this report are positioned to enhance treatment value, expand access, and maintain competitive advantage as the market evolves.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising competition among generic PDE5 inhibitors driving down prices and expanding patient access
5.2. Integration of telemedicine and e-prescribing solutions improving adherence for ED patients
5.3. Emergence of rapid-onset sildenafil formulations designed to enhance spontaneity in sexual activity
5.4. Development of oral combination therapies addressing erectile function and cardiovascular comorbidities
5.5. Strategic partnerships between pharmaceutical companies and digital health startups enabling personalized ED care
5.6. Growing pipeline of alternative mechanism oral agents targeting melanocortin receptors for erectile dysfunction
5.7. Regulatory approvals of once-daily tadalafil generics improving long-term compliance in diverse patient populations
5.8. Increasing investment in natural and plant-derived phosphodiesterase inhibitors as alternative ED treatments
5.9. Entry of emerging-market players expanding oral ED drug availability in Asia Pacific and Latin American markets
5.10. Advancements in lipid-based oral delivery systems boosting bioavailability of PDE5 inhibitors and reducing side effects
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Medications for Erectile Dysfunction Market, by Drug
8.1. Introduction
8.2. Avanafil
8.2.1. 100 Mg
8.2.2. 200 Mg
8.2.3. 50 Mg
8.3. Sildenafil
8.3.1. 100 Mg
8.3.2. 25 Mg
8.3.3. 50 Mg
8.4. Tadalafil
8.4.1. 10 Mg
8.4.2. 20 Mg
8.4.3. 5 Mg
8.5. Vardenafil
8.5.1. 10 Mg
8.5.2. 20 Mg
8.5.3. 5 Mg
9. Oral Medications for Erectile Dysfunction Market, by Brand
9.1. Introduction
9.2. Branded
9.2.1. Cialis
9.2.2. Levitra
9.2.3. Stendra
9.2.4. Viagra
9.3. Generic
9.3.1. Avanafil
9.3.2. Sildenafil Citrate
9.3.3. Tadalafil
9.3.4. Vardenafil
10. Oral Medications for Erectile Dysfunction Market, by Dosage Strength
10.1. Introduction
10.2. 100 Mg
10.3. 200 Mg
10.4. 25 Mg
10.5. 50 Mg
11. Oral Medications for Erectile Dysfunction Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Oral Medications for Erectile Dysfunction Market, by Age Group
12.1. Introduction
12.2. 45-60 Years
12.3. 60+ Years
12.4. Under 45 Years
13. Americas Oral Medications for Erectile Dysfunction Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Oral Medications for Erectile Dysfunction Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Oral Medications for Erectile Dysfunction Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Eli Lilly and Company
16.3.3. Bayer AG
16.3.4. Vivus, Inc.
16.3.5. Teva Pharmaceutical Industries Ltd.
16.3.6. Viatris Inc.
16.3.7. Sandoz International GmbH
16.3.8. Dr. Reddy's Laboratories Ltd.
16.3.9. Cipla Ltd.
16.3.10. Sun Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET: RESEARCHAI
FIGURE 26. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET: RESEARCHSTATISTICS
FIGURE 27. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET: RESEARCHCONTACTS
FIGURE 28. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 200 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 200 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 25 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 25 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 10 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 10 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 20 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 20 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 5 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 10 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 10 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 20 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 20 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 5 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY CIALIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY CIALIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY LEVITRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY LEVITRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STENDRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STENDRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VIAGRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VIAGRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL CITRATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL CITRATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 200 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 200 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 25 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 25 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 50 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 45-60 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 45-60 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 60+ YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY 60+ YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY UNDER 45 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY UNDER 45 YEARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 151. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 152. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 153. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 154. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 155. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 156. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 157. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 158. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 159. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 160. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 161. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 162. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 163. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 164. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 165. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 166. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 167. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 172. CANADA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 183. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 184. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 185. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 186. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY VARDENAFIL, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRAND, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM ORAL MEDICATIONS FOR ERECTILE DYSF

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oral Medications for Erectile Dysfunction market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Erectile Dysfunction Market - Global Forecast 2025-2030 - Product Image

Erectile Dysfunction Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Drugs for Erectile Dysfunction Market Report 2025 - Product Image

Drugs for Erectile Dysfunction Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Drugs for Sexual Dysfunction Market - Global Forecast 2025-2030 - Product Image

Drugs for Sexual Dysfunction Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Erectile Dysfunction Drugs - Global Strategic Business Report - Product Image

Erectile Dysfunction Drugs - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.